ADMA Biologics, Inc. (ADMA)CEO sold ~$241K

~$241K

Approx. value · 15K sh @ $16.08

2.29M

Holds after · shares reported

Traded

Feb 17, 2026

Filed

Feb 18, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Jan 12, 2026Company filing · Form 8-K · Results, Reg FDReported its results, and shared information with investors
2. Feb 17, 2026 · this disclosureInsiderCEO sold ~$241K of ADMA shares in the open market

What came next

1. Feb 17, 2026InsiderCEO sold ~$96K of ADMA shares in the open market
2. Feb 20, 2026Company filing · Form 8-K · Results, Executive changeChanged a top executive or board member, and reported its results“On February 20, 2026, Brad Tade notified the Company that he is retiring from his position as Chief Financial Officer and Treasurer of the Company effective at the close of business on February 25, 2026, following the filing of the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 (the “2025 Form 10-K”).”
3. Mar 5, 2026Insider · First insider buy since Aug 2023Director purchased ~$110K of ADMA shares in the open market
4. Mar 6, 2026InsiderDirector purchased ~$108K of ADMA shares in the open market
5. Mar 9, 2026InsiderOfficer sold ~$158K of ADMA shares in the open market
6. Mar 16, 2026Insider · 1 personInsiders: 2 sales (~$318K)
7. May 6, 2026Company filing · Form 8-K · ResultsReported its results
8. May 11, 2026Insider · First buy since 2023Director purchased ~$100K of ADMA shares in the open market
9. May 12, 2026InsiderDirector purchased ~$100K of ADMA shares in the open market
10. May 27, 2026InsiderDirector purchased ~$51K of ADMA shares in the open market

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for ADMA Biologics, Inc.

For ADMA Biologics, Inc., OQRO holds 4 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ADMA page.

Other recent filings by Adam S Grossman, President and CEO

• SEC Form 4 at ADMA Biologics, Inc. (ADMA)Mar 18, 2026
• SEC Form 4 at ADMA Biologics, Inc. (ADMA)Mar 18, 2026
• SEC Form 4 at ADMA Biologics, Inc. (ADMA)Feb 18, 2026
• SEC Form 4 at ADMA Biologics, Inc. (ADMA)Dec 17, 2025
• SEC Form 4 at ADMA Biologics, Inc. (ADMA)Dec 17, 2025

The full history of Adam S Grossman, President and CEO is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at ADMA Biologics, Inc.

• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRMay 29, 2026
• SEC Form 4May 28, 2026

Everything OQRO holds on this company is on its ADMA page.